Menu
Search icon
  1. Home Page
    2. ›
  2. Counties
    3. ›
  3. Palm Beach
    4. ›
  4. 33458
    5. ›
  5. DELUGE BIOTECHNOLOGIES, INC.

DELUGE BIOTECHNOLOGIES, INC. - Florida Company Profile

Company claim

Is this your business?

Get access!

Company Details

Entity Name: DELUGE BIOTECHNOLOGIES, INC.
Jurisdiction: FLORIDA
Filing Type: Foreign Profit
Status: Active

The business entity is active. This status indicates that the business is currently operating and compliant with state regulations, suggesting a lower risk profile for lenders and potentially better creditworthiness.

Date Filed: 08 May 2017 (8 years ago)
Last Event: REINSTATEMENT
Event Date Filed: 10 Jun 2019 (6 years ago)
Document Number: F17000002081
FEI/EIN Number 82-0637617

Federal Employer Identification (FEI) Number assigned by the IRS.
Address: 6671 W INDIANTOWN ROAD STE 50-325, JUPITER, FL, 33458, US
Mail Address: 6671 W INDIANTOWN ROAD STE 50-325, JUPITER, FL, 33458, US
ZIP code: 33458
County: Palm Beach
Place of Formation: DELAWARE

Key Officers & Management

Name Role Address
UTSET OFELIA President 8711 SE SOMERSET ISLAND WAY, JUPITER, FL, 33458
UTSET OFELIA Dr. Agent 8711 SE SOMERSET ISLAND WAY, JUPITER, FL, 33458

U.S. Small Business Administration Profile

The U.S. Small Business Administration (SBA) helps Americans start, grow, and build resilient businesses.

Note: SBA was created in 1953 as an independent agency of the federal government to aid, counsel, assist and protect the interests of small business concerns; preserve free competitive enterprise; and maintain and strengthen the overall economy of our nation. SBA reviews Congressional and testifies on behalf of small businesses. It assesses the impact of regulatory burden on small businesses.

Website:
http://www.delugebiotechnologies.com/
Phone Number:
214-563-2975
E-mail Address:
ofelia.utset@delugebiotechnologies.com
Contact Person:
OFELIA UTSET
Ownership and Self-Certifications:
Self-Certified Small Disadvantaged Business
User ID:
P2784715

Form 5500 Series

Employer Identification Number (EIN):
820637617
Plan Year:
2023
Number Of Participants:
8
Sponsors Telephone Number:
5617487559
File:
View File
Plan Year:
2022
Number Of Participants:
7
Sponsors Telephone Number:
5617487559
File:
View File
Plan Year:
2021
Number Of Participants:
5
Sponsors Telephone Number:
5617487559
File:
View File
Plan Year:
2020
Number Of Participants:
3
Sponsors Telephone Number:
2145632975
File:
View File

Events

Event Type Filed Date Value Description
REINSTATEMENT 2019-06-10 - -
REGISTERED AGENT NAME CHANGED 2019-06-10 UTSET, OFELIA, Dr. -
REVOKED FOR ANNUAL REPORT 2018-09-28 - -

Documents

Name Date
ANNUAL REPORT 2024-01-28
ANNUAL REPORT 2023-01-23
ANNUAL REPORT 2022-02-02
ANNUAL REPORT 2021-02-13
ANNUAL REPORT 2020-02-05
REINSTATEMENT 2019-06-10
Foreign Profit 2017-05-08

USAspending Awards / Financial Assistance

Date:
2023-07-28
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
HIGH-THROUGHPUT SCREENING FOR THE DISCOVERY OF PROTEIN-BINDING FRAGMENTS - PROJECT SUMMARY FRAGMENT BASED DRUG DISCOVERY PROGRAMS BEGIN WITH THE IDENTIFICATION OF LOW MOLECULAR COMPOUNDS THAT BIND WEAKLY TO THE PROTEIN OF INTEREST (POI). POI-BINDING FRAGMENTS ARE THEN ELABORATED AND/OR LINKED TOGETHER TO PROVIDE LEAD COMPOUNDS. CURRENT METHODS FOR SCREENING FRAGMENT LIBRARIES HAVE LOW THROUGHPUT AND MANY REQUIRE LARGE AMOUNTS OF THE POI, OFTEN IN ISOTOPICALLY LABELED FORM. THIS PROPOSAL WILL ESTABLISH A NOVEL SCREENING PLATFORM CAPABLE OF ANALYZING HUNDREDS OF POTENTIAL FRAGMENT-PROTEIN INTERACTIONS IN A SINGLE TUBE. WE WILL CREATE DOZENS OF FLUORESCENTLY ENCODED ONE BEAD ONE COMPOUND (OBOC) LIBRARIES COMPRISED OF HUNDREDS OF LOW MOLECULAR WEIGHT COMPOUNDS. THEY WILL BE SCREENED AGAINST A FLUORESCENTLY LABELED, TETRAMERIC FORM OF THE POI. AVIDITY EFFECTS WILL STABILIZE THE WEAK INTERACTIONS SUFFICIENTLY TO ALLOW THE BEADS TO BE ANALYZED BY FLOW CYTOMETRY, IDENTIFYING THOSE CAPABLE OF RETAINING THE POI. IF NECESSARY, PROXIMITY LABELING WILL BE EXPLORED TO INCREASE THE SENSITIVITY OF THE SYSTEM. THIS TECHNOLOGY WILL BE EMPLOYED TO DISCOVER NOVEL FRAGMENTS THAT ENGAGE THE VHL E3 UBIQUITIN LIGASE.
Obligated Amount:
265540.44
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2022-03-29
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
ASYMMETRIC SYNTHESIS OF DNA-ENCODED LIBRARIES OF NATURAL PRODUCT-LIKE COMPOUNDS. - PROJECT SUMMARY DNA-ENCODED LIBRARY (DEL) TECHNOLOGY IS A POWERFUL METHOD FOR THE DISCOVERY OF PROTEIN LIGANDS. IT IS CAPABLE OF SCREENING MILLIONS OF SMALL MOLECULES FOR A FRACTION OF THE PRICE REQUIRED TO CONDUCT TRADITIONAL, FUNCTION-BASED HIGH-THROUGHPUT SCREENS. A CURRENT LIMITATION OF THE TECHNOLOGY IS THAT IT IS DIFFICULT TO INCORPORATE LARGE NUMBERS OF SP3 CHIRAL CENTERS INTO LIBRARIES, SINCE FEW, IF ANY, ASYMMETRIC SYNTHESIS METHODS HAVE BEEN VALIDATED FOR DEL SYNTHESIS. THIS IS UNFORTUNATE, SINCE THERE IS GENERAL AGREEMENT THAT DELS WITH MORE NATURAL PRODUCT-LIKE CHARACTERISTICS WOULD BE A HIGHLY VALUABLE SOURCE OF DRUG LEADS. HERE WE WILL ADAPT ASYMMETRIC ORGANOCATALYTIC ALDOL REACTIONS FOR SOLID-PHASE SYNTHESIS OF DELS. THIS EFFORT WILL INVOLVE THE DEVELOPMENT OF A NOVEL PROXIMITY CATALYSIS METHOD TO DRIVE OTHERWISE RECALCITRANT REACTIONS. IF SUCCESSFUL, THIS WORK WILL ENABLE THE SYNTHESIS OF DELS OF UNPRECEDENTED STEREOCHEMICAL COMPLEXITY.
Obligated Amount:
223389.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2021-09-08
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
SYNTHESIS AND SCREENING OF DNA-ENCODED LIBRARIES OF NON-PEPTIDIC MACROCYCLES - PROJECT SUMMARY MOST DRUGS TARGET PROTEINS WITH RELATIVELY DEEP POCKETS, SUCH AS ENZYME ACTIVE SITES. HOWEVER, SCREENING COLLECTIONS COMPRISED OF THESE TRADITIONAL RULE OF 5-COMPLIANT MOLECULES HAVE CONSISTENTLY FAILED TO PROVIDE HIGH QUALITY DRUG LEADS FOR MANY TARGETS THAT FUNCTION VIA PROTEIN-NUCLEIC ACID AND PROTEIN-PROTEIN INTERACTIONS (PPIS). THESE ARE THE “DIFFICULT” OR “UNDRUGGABLE” PROTEIN TARGETS, WHICH BY SOME ESTIMATES COMPRISE UP TO 85% OF THE HUMAN PROTEOME. THE IMPORTANCE OF THESE TYPES OF PPIS HAS BEEN WELL NOTED IN CANCER THERAPEUTICS AND MORE RECENTLY IN THE INFECTIOUS DISEASES FIELD WHERE PPIS PLAY A ROLE IN THE INTERACTION BETWEEN HOST AND PATHOGEN. MACROCYCLIC PEPTIDES (MPS) ARE CAPABLE OF ENGAGING THESE SHALLOW, SOLVENT EXPOSED SURFACES, BUT MOST MPS ARE NOT CELL PERMEABLE. THIS HIGHLIGHTS THE CRITICAL NEED FOR THE DEVELOPMENT OF LIBRARIES OF NOVEL, CELL PERMEABLE COMPOUNDS CAPABLE OF ENGAGING PPI SURFACES. IN PHASE I, WE SUCCESSFULLY DEMONSTRATED THE FEASIBILITY OF GENERATING AND SCREENING LARGE DNA-ENCODED LIBRARIES OF NON-PEPTIDIC MACROCYCLES, WHICH HAVE THE APPROPRIATE CHARACTERISTICS TO ADDRESS THIS NEED. IN THIS PHASE II PROJECT, WE WILL EXPAND THE CHEMICAL DIVERSITY OF THESE LIBRARIES, TEST THEM AGAINST SEVERAL DIFFICULT TARGETS, AND ESTABLISH METHODS TO EVOLVE PRIMARY SCREENING HITS DERIVED FROM THE LIBRARIES INTO HIGH-QUALITY DRUG LEADS.
Obligated Amount:
1468040.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2021-01-23
Link:
View on USAspending
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO AID SMALL BUSINESSES IN MAINTAINING WORK FORCE DURING COVID-19 PANDEMIC.
Obligated Amount:
0.00
Face Value Of Loan:
62777.50
Total Face Value Of Loan:
62777.50
Date:
2020-04-28
Link:
View on USAspending
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO AID SMALL BUSINESSES IN MAINTAINING WORK FORCE DURING COVID-19 PANDEMIC.
Obligated Amount:
0.00
Face Value Of Loan:
47700.00
Total Face Value Of Loan:
47700.00

Paycheck Protection Program

Date Approved:
2020-04-28
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Initial Approval Amount:
47700
Current Approval Amount:
47700
Race:
Unanswered
Ethnicity:
Unknown/NotStated
Gender:
Unanswered
Veteran:
Unanswered
Forgiveness Amount:
47975.6
Date Approved:
2021-01-20
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Initial Approval Amount:
62777.5
Current Approval Amount:
62777.5
Race:
Unanswered
Ethnicity:
Unknown/NotStated
Gender:
Unanswered
Veteran:
Unanswered
Forgiveness Amount:
63040.82

Reviews Leave a review

This company hasn't received any reviews.

Companies related by officers

UTSET OFELIA

DELUGE BIOTECHNOLOGIES HOLDINGS, LLC - Active
Florida Limited Liability Co. (2017 )

Companies related by address

No other companies in our directory share the same address as DELUGE BIOTECHNOLOGIES, INC.

Date of last update: 01 Jun 2025

Sources: Florida Department of State

Privacy policy Policy
About us About us
Contacts Contact us

© 2025 flprofile.com, Part of Big Data Integrated